日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Finance

Health stocks appear hottest, 'risky'

China Daily | Updated: 2018-06-04 09:32
Share
Share - WeChat
Saleswomen manage the stall of Chinese herbal medicine firm Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd at the company's museum in Zhangzhou, Fujian province. [Photo by Lin Shanchuan / Xinhua]

A company that makes medicine out of snake gall bladders has seen its shares more than double this year as healthcare companies become China's hottest stocks.

In a market buffeted by the fallout from the US trade disputes, mainland investors have sought shelter in firms like traditional medicine maker Zhangzhou Pien Tze Huang Pharmaceutical Co, that make almost all their sales at home. It also does not hurt that China's healthcare industry is expected to post above-average profit growth of more than 20 percent for the next three to five years, Bloomberg estimates show, as China's massive population ages and gets wealthier.

That's all adding up to scorching gains: drugmakers and other health stocks are by far the best-performing corner of the Chinese market in 2018, up nearly 30 percent.

Valuations - now at levels unseen in a decade - are shaping up as the biggest threat to a rally that's managed to overcome equity losses in almost every other industry.

"The sector may touch a valuation ceiling soon if it rallies further," said Sun Jianbo, president of Beijing-based China Vision Capital Management. "However fast the future growth might be, it takes time for companies to realize that."

Bulls are optimistic medical reforms, such as faster approvals for new drugs, will help established companies accelerate earnings growth even more quickly.

Market leaders like Jiangsu Hengrui Medicine Co stand to benefit from nationwide efforts to promote the use of generic drugs in treatment, according to Dai Ming, Shanghai-based fund manager with Hengsheng Asset Management Co.

Companies with solid distribution networks will be lifted by another reform to lower the price of drugs dispensed by hospitals and cut intermediaries in drug sales, he said.

"Many healthcare firms are entering an innovation cycle - they are able to develop new drugs which, if successful, will contribute in a big way to future earnings," said Dai. "Valuations have expanded, but they are not yet at outrageous levels."

Zhang Jinyang, chief pharmaceutical analyst at Dongxing Securities, said consumption upgrade, supply-side structural reform and institutional investors' low positions in pharmaceutical shares can be the main reasons for the strong performance of healthcare stocks in the capital market.

Zhang said the situation will continue, and companies with solid business operations and high growth will be popular among investors.

Keeping faith is proving rewarding. Hong Kong-listed CSPC Pharmaceutical Group Ltd surged to a fresh record on Monday after better-than-expected earnings prompted brokerages from Goldman Sachs Group Inc to Credit Suisse Group AG to lift their price targets. Other drugmakers including 3SBio Inc soared.

Yet the risks of a reversal are rising. Chinese pharmaceutical stocks are most expensive relative to global peers in a decade. Valuations on the CSI 300 Health Care gauge have hit more than 36 times forward 12-month earnings, compared with an all-time average of 23 times.

CSPC Pharma trades at 40 times projected profits, far higher than Tencent Holdings Ltd or Alibaba Group Holding Ltd.

But, investors betting that red-hot Chinese shares can only go in one direction have been disappointed before.

For instance, Ping An Group Insurance Co, which nearly doubled in Shanghai last year, has tumbled more than 10 percent in 2018, while record earnings have failed to lift analysts' favorite Tencent out of its trough.

The medical sector is in need of a temperature check, given how high valuations have soared, said Gu Yongtao, an analyst with Cinda Securities Co. "Healthcare shares are looking a bit risky right now."

Bloomberg - China Daily

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 日韩精品一区二区三区 | 久草手机在线播放 | 日韩免费视频一区二区 | 中文字幕第一页在线 | 91精品观看91久久久久久 | 99人中文字幕亚洲区 | 青青草一区 | 欧美日韩一区,二区,三区,久久精品 | av大片| 日韩欧美中文字幕在线播放 | 中国一级特黄真人毛片免费看 | 亚洲精品一区二区三区福利 | 久久视频这里只精品99 | 一区二区三区在线电影 | 综合精品一区 | 亚洲色图欧美色 | 一区二区高清视频 | 亚洲天堂久久 | 欧美18一12sex性处hd | 日本久久综合视频 | 欧美日韩亚洲视频 | 青青青国产观看免费视频 | 欧美性受 | 日本韩国一区二区三区 | 欧美激情在线播放 | 亚洲国产一区二区三区四区 | 91在线播放免费不卡无毒 | 国产在线精品一区二区 | 2017最新h无码动漫 | 久久久久99 | 一区二区三区高清 | 国产一区二区久久久 | a级黄色片视频 | 青娱乐国产精品 | 在线观看91精品国产入口 | 国产网站大全 | 国产一国产一区秋霞在线观看 | 欧美三极 | 国产色综合一区二区三区 | 欧美日韩不卡在线 | 二级黄的全免费视频 |